SNOA

Sonoma Pharmaceuticals' stock price has declined significantly in the past six months. On April 30, 2026, the company closed a $4 million stock and warrant sale. On April 27, 2026, a 2.96 million-unit offering priced at $1.35 per unit led to a -36.67% single-day stock decline. On February 10, 2026, Sonoma Pharmaceuticals reported its third fiscal quarter 2026 financial results, with a GAAP EPS of -$0.48 and revenue of $4.3 million, missing consensus estimates. On November 4, 2025, the company reported its second fiscal quarter 2026 financial results, showing record quarterly revenue of $5.6 million, a 57% increase year-over-year.